| Income Statement | 2025-09-30 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Revenues | 5,604 | 3,564 | 3,579 | 3,391 |
| Cost of revenues | 3,484 | 2,294 | 2,218 | 2,085 |
| Gross profit | 2,120 | 1,270 | 1,361 | 1,306 |
| Research and development | 575 | 427 | 506 | 470 |
| Selling, general and administrative | 1,882 | 1,874 | 1,705 | 2,009 |
| Total operating expenses | 2,457 | 2,301 | 2,211 | 2,479 |
| Loss from operations | -337 | -1,031 | -850 | -1,173 |
| Other (expense) income, net | -394 | 112 | 387 | 176 |
| Net loss before income taxes | -731 | -919 | -463 | -997 |
| Income tax benefit (expense) | -197 | 9 | 147 | 146 |
| Net loss | -534 | -928 | -610 | -1,143 |
| Foreign currency translation adjustments | 205 | -357 | -593 | -881 |
| Comprehensive loss | -329 | -1,285 | -1,203 | -2,024 |
| Net loss per share basic | -0.32 | -0.63 | -0.59 | -0.07 |
| Net loss per share diluted | -0.32 | -0.63 | -0.59 | -0.07 |
| Weighted-average number of shares outstanding basic | 1,646,000 | 1,464,000 | 1,034,000 | 17,029,000 |
| Weighted-average number of shares outstanding diluted | 1,646,000 | 1,464,000 | 1,034,000 | 17,029,000 |
Sonoma Pharmaceuticals, Inc. (SNOA)
Sonoma Pharmaceuticals, Inc. (SNOA)